1
|
Griñán‐Ferré C, Jarné‐Ferrer J, Bellver‐Sanchís A, Codony S, Puigoriol‐Illamola D, Sanfeliu C, Oh Y, Lee S, Vázquez S, Pallàs M. Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics. CNS Neurosci Ther 2024; 30:e14511. [PMID: 37905690 PMCID: PMC11017401 DOI: 10.1111/cns.14511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 09/21/2023] [Accepted: 10/09/2023] [Indexed: 11/02/2023] Open
Abstract
BACKGROUND Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD. AIMS The aim of the study was to unveil new molecular pathways driving neuroprotection through sEH, we used an optimized, potent, and selective sEH inhibitor (sEHi, UB-SCG-51). MATERIALS AND METHODS UB-SCG-51 was tested in neuroblastoma cell line, SH-SY5Y, in primary mouse and human astrocytes cultures challenged with proinflammatory insults and in microglia cultures treated with amyloid oligomers, as well as in mice AD model (5XFAD). RESULTS UB-SCG-51 (10 and 30 μM) prevented neurotoxic reactive-astrocyte conversion in primary mouse astrocytes challenged with TNF-α, IL-1α, and C1q (T/I/C) combination for 24 h. Moreover, in microglial cultures, sEHi reduced inflammation and glial activity. In addition, UB-SCG-51 rescued 5XFAD cognitive impairment, reducing the number of Amyloid-β plaques and Tau hyperphosphorylation accompanied by a reduction in neuroinflammation and apoptotic markers. Notably, a transcriptional profile analysis revealed a new pathway modulated by sEHi treatment. Specifically, the eIF2α/CHOP pathway, which promoted the endoplasmic reticulum response, was increased in the 5XFAD-treated group. These findings were confirmed in human primary astrocytes by combining sEHi and eIF2α inhibitor (eIF2αi) treatment. Besides, combining both treatments resulted in increased in C3 gene expression after T/I/C compared with the group treated with sEHi alone in cultures. DISCUSSION Therefore, sEHi rescued cognitive impairment and neurodegeneration in AD mice model, based on the reduction of inflammation and eIF2α/CHOP signaling pathway. CONCLUSIONS In whole, our results support the concept that targeting neuroinflammation through sEH inhibition is a promising therapeutic strategy to fight against Alzheimer's disease with additive and/or synergistic activities targeting neuroinflammation and cell stress.
Collapse
Affiliation(s)
- Christian Griñán‐Ferré
- Department of Pharmacology and Therapeutic ChemistryInstitut de Neurociències‐Universitat de BarcelonaBarcelonaSpain
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIIMadridSpain
| | - Júlia Jarné‐Ferrer
- Department of Pharmacology and Therapeutic ChemistryInstitut de Neurociències‐Universitat de BarcelonaBarcelonaSpain
| | - Aina Bellver‐Sanchís
- Department of Pharmacology and Therapeutic ChemistryInstitut de Neurociències‐Universitat de BarcelonaBarcelonaSpain
| | - Sandra Codony
- Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB)University of Barcelona (UB)BarcelonaSpain
| | - Dolors Puigoriol‐Illamola
- Department of Pharmacology and Therapeutic ChemistryInstitut de Neurociències‐Universitat de BarcelonaBarcelonaSpain
| | - Coral Sanfeliu
- Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones Científicas (CSIC)BarcelonaSpain
| | - Yumin Oh
- Neuraly Inc.MarylandGaithersburgUSA
| | | | - Santiago Vázquez
- Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB)University of Barcelona (UB)BarcelonaSpain
| | - Mercè Pallàs
- Department of Pharmacology and Therapeutic ChemistryInstitut de Neurociències‐Universitat de BarcelonaBarcelonaSpain
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIIMadridSpain
| |
Collapse
|
2
|
Codony S, Entrena JM, Calvó-Tusell C, Jora B, González-Cano R, Osuna S, Corpas R, Morisseau C, Pérez B, Barniol-Xicota M, Griñán-Ferré C, Pérez C, Rodríguez-Franco MI, Martínez AL, Loza MI, Pallàs M, Verhelst SHL, Sanfeliu C, Feixas F, Hammock BD, Brea J, Cobos EJ, Vázquez S. Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. J Med Chem 2022; 65:13660-13680. [PMID: 36222708 PMCID: PMC9620236 DOI: 10.1021/acs.jmedchem.2c00515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratori
de Química Farmacèutica (Unitat Associada al CSIC),
Facultat de Farmàcia i Ciències de l’Alimentació,
and Institute of Biomedicine (IBUB), Universitat
de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - José M. Entrena
- Animal
Behavior Research Unit, Scientific Instrumentation Center, Parque
Tecnológico de Ciencias de la Salud, University of Granada, Armilla, Granada 18100, Spain
| | - Carla Calvó-Tusell
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain
| | - Beatrice Jora
- Laboratori
de Química Farmacèutica (Unitat Associada al CSIC),
Facultat de Farmàcia i Ciències de l’Alimentació,
and Institute of Biomedicine (IBUB), Universitat
de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - Rafael González-Cano
- Department
of Pharmacology, Faculty of Medicine and Biomedical Research Center
(Neurosciences Institute), Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, Granada 18016, Spain
| | - Sílvia Osuna
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain,Institució
Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
| | - Rubén Corpas
- Institute
of Biomedical Research of Barcelona (IIBB), CSIC and IDIBAPS, Barcelona 08036, Spain
| | - Christophe Morisseau
- Department
of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, California 95616, United States
| | - Belén Pérez
- Department
of Pharmacology, Therapeutics and Toxicology, Institute of Neurosciences, Autonomous University of Barcelona, Bellaterra, Barcelona 08193, Spain
| | - Marta Barniol-Xicota
- Laboratory
of Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven—University of Leuven, Herestraat 49 box B901, Leuven 3000, Belgium
| | - Christian Griñán-Ferré
- Pharmacology
Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,
Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona (NeuroUB), Av. Joan XXIII 27-31, Barcelona 08028, Spain
| | - Concepción Pérez
- Institute of Medicinal Chemistry, Spanish
National Research Council (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain
| | - María Isabel Rodríguez-Franco
- Institute of Medicinal Chemistry, Spanish
National Research Council (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain
| | - Antón L. Martínez
- Drug Screening
Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain
| | - M. Isabel Loza
- Drug Screening
Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain
| | - Mercè Pallàs
- Pharmacology
Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,
Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona (NeuroUB), Av. Joan XXIII 27-31, Barcelona 08028, Spain
| | - Steven H. L. Verhelst
- Laboratory
of Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven—University of Leuven, Herestraat 49 box B901, Leuven 3000, Belgium,Leibniz Institute
for Analytical Sciences ISAS, AG Chemical
Proteomics, Otto-Hahn-Str.
6b, Dortmund 44227, Germany
| | - Coral Sanfeliu
- Institute
of Biomedical Research of Barcelona (IIBB), CSIC and IDIBAPS, Barcelona 08036, Spain
| | - Ferran Feixas
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain
| | - Bruce D. Hammock
- Department
of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, California 95616, United States
| | - José Brea
- Drug Screening
Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain
| | - Enrique J. Cobos
- Department
of Pharmacology, Faculty of Medicine and Biomedical Research Center
(Neurosciences Institute), Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, Granada 18016, Spain
| | - Santiago Vázquez
- Laboratori
de Química Farmacèutica (Unitat Associada al CSIC),
Facultat de Farmàcia i Ciències de l’Alimentació,
and Institute of Biomedicine (IBUB), Universitat
de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain,. Phone: +34 934024533
| |
Collapse
|
3
|
Vázquez S, Codony S, Entrena JM, Jora B, González‐Cano R, Loza MI, Brea J, Morisseau C, Bartra C, Sanfeliu C, Hammock BD, Cobos EJ. Soluble Epoxide Hydrolase Inhibitors: Design, Synthesis,
in vitro
Profiling and
in vivo
Evaluation in Murine Models of Pain. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r2955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Faculty of Pharmacy and Food Sciences, Universitat de Barcelona and IBUBBarcelona
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Faculty of Pharmacy and Food Sciences, Universitat de Barcelona and IBUBBarcelona
| | - José M. Entrena
- School of Medicine, University of Granada, and Ibs. GranadaGranada
| | - Beatrice Jora
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Faculty of Pharmacy and Food Sciences, Universitat de Barcelona and IBUBBarcelona
| | | | - M. I. Loza
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center. University of Santiago de Compostela (USC)Santiago de Compostela
| | - Jose Brea
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center. University of Santiago de Compostela (USC), Santiago de Compostela, SpainSantiago de Compostela
| | - Christophe Morisseau
- UC Davis Comprehensive Cancer Center, University of California, Davis, CA, USADavisCA
| | - Clara Bartra
- Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, SpainBarcelona
| | - Coral Sanfeliu
- Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, Barcelona, SpainBarcelona
| | - Bruce D. Hammock
- UC Davis Comprehensive Cancer Center, University of California, Davis, CA, USADavisCA
| | - Enrique J. Cobos
- Department of PharmacologySchool of MedicineUniversity of Granada, and Ibs. Granada, Granada, SpainGranada
| |
Collapse
|
4
|
Codony S, Pont C, Griñán-Ferré C, Di Pede-Mattatelli A, Calvó-Tusell C, Feixas F, Osuna S, Jarné-Ferrer J, Naldi M, Bartolini M, Loza MI, Brea J, Pérez B, Bartra C, Sanfeliu C, Juárez-Jiménez J, Morisseau C, Hammock BD, Pallàs M, Vázquez S, Muñoz-Torrero D. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. J Med Chem 2022; 65:4909-4925. [PMID: 35271276 PMCID: PMC8958510 DOI: 10.1021/acs.jmedchem.1c02150] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratory
of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy
and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Caterina Pont
- Laboratory
of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy
and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Christian Griñán-Ferré
- Pharmacology
Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,
Faculty of Pharmacy and Food Sciences, and Institute of Neurosciences, University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Ania Di Pede-Mattatelli
- Department
of Pharmacy and Pharmaceutical Technology and Physical Chemistry,
Faculty of Pharmacy and Food Sciences, and Institute of Theoretical
and Computational Chemistry (IQTCUB), University
of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Carla Calvó-Tusell
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, E-17003 Girona, Spain
| | - Ferran Feixas
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, E-17003 Girona, Spain
| | - Sílvia Osuna
- CompBioLab
Group, Departament de Química and Institut de Química
Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, E-17003 Girona, Spain,Institució
Catalana de Recerca i Estudis Avançats (ICREA), E-08010 Barcelona, Spain
| | - Júlia Jarné-Ferrer
- Pharmacology
Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,
Faculty of Pharmacy and Food Sciences, and Institute of Neurosciences, University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Marina Naldi
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro, 6, I-40126 Bologna, Italy
| | - Manuela Bartolini
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro, 6, I-40126 Bologna, Italy
| | - María Isabel Loza
- BioFarma
Research Group, Centro Singular de Investigación en Medicina
Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, Av. de Barcelona s/n, E-15782 Santiago de Compostela, Spain
| | - José Brea
- BioFarma
Research Group, Centro Singular de Investigación en Medicina
Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, Av. de Barcelona s/n, E-15782 Santiago de Compostela, Spain
| | - Belén Pérez
- Department
of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, E-08193 Bellaterra, Spain
| | - Clara Bartra
- Institute
of Biomedical Research of Barcelona, CSIC and Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149, E-08036 Barcelona, Spain
| | - Coral Sanfeliu
- Institute
of Biomedical Research of Barcelona, CSIC and Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149, E-08036 Barcelona, Spain
| | - Jordi Juárez-Jiménez
- Department
of Pharmacy and Pharmaceutical Technology and Physical Chemistry,
Faculty of Pharmacy and Food Sciences, and Institute of Theoretical
and Computational Chemistry (IQTCUB), University
of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Christophe Morisseau
- Department
of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, California 95616, United States
| | - Bruce D. Hammock
- Department
of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, California 95616, United States
| | - Mercè Pallàs
- Pharmacology
Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,
Faculty of Pharmacy and Food Sciences, and Institute of Neurosciences, University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
| | - Santiago Vázquez
- Laboratory
of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy
and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain,. Phone: (+34) 934024533
| | - Diego Muñoz-Torrero
- Laboratory
of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy
and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028 Barcelona, Spain,. Phone: (+34) 934024533
| |
Collapse
|
5
|
Martín-López J, Codony S, Bartra C, Morisseau C, Loza MI, Sanfeliu C, Hammock BD, Brea J, Vázquez S. 2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity. Pharmaceuticals (Basel) 2021; 14:ph14121323. [PMID: 34959721 PMCID: PMC8703317 DOI: 10.3390/ph14121323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/14/2021] [Accepted: 12/16/2021] [Indexed: 11/16/2022] Open
Abstract
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU.
Collapse
Affiliation(s)
- Juan Martín-López
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l′Alimentació, Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain; (J.M.-L.); (S.C.)
- Institute of Biomedicine (IBUB), Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l′Alimentació, Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain; (J.M.-L.); (S.C.)
- Institute of Biomedicine (IBUB), Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain
| | - Clara Bartra
- Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, C/Roselló 161, 08036 Barcelona, Spain; (C.B.); (C.S.)
| | - Christophe Morisseau
- Department of Entomology and Nematology, University of California Davis, One Shields Avenue, Davis, CA 95616, USA; (C.M.); (B.D.H.)
- Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis, CA 95616, USA
| | - María Isabel Loza
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain;
| | - Coral Sanfeliu
- Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC and IDIBAPS, C/Roselló 161, 08036 Barcelona, Spain; (C.B.); (C.S.)
| | - Bruce D. Hammock
- Department of Entomology and Nematology, University of California Davis, One Shields Avenue, Davis, CA 95616, USA; (C.M.); (B.D.H.)
- Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis, CA 95616, USA
| | - José Brea
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain;
- Correspondence: (J.B.); (S.V.); Tel.: +34-881-815-459 (J.B.); +34-934-024-533 (S.V.)
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l′Alimentació, Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain; (J.M.-L.); (S.C.)
- Institute of Biomedicine (IBUB), Universitat de Barcelona, Avinguda Joan XXIII 27–31, 08028 Barcelona, Spain
- Correspondence: (J.B.); (S.V.); Tel.: +34-881-815-459 (J.B.); +34-934-024-533 (S.V.)
| |
Collapse
|
6
|
Codony S, Calvó-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Pérez C, Rodríguez-Franco MI, Pizarro-Delgado J, Corpas R, Griñán-Ferré C, Pallàs M, Sanfeliu C, Vázquez-Carrera M, Hammock BD, Feixas F, Vázquez S. From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. J Med Chem 2021; 64:5429-5446. [PMID: 33945278 PMCID: PMC8634379 DOI: 10.1021/acs.jmedchem.0c01601] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
![]()
The
pharmacological inhibition of soluble epoxide hydrolase (sEH)
is efficient for the treatment of inflammatory and pain-related diseases.
Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl
moieties, such as the clinical candidates AR9281 or EC5026. Herein,
in a new series of sEHIs, these hydrophobic moieties have been merged
in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent
inhibitory activities against sEH. Molecular dynamics simulations
suggested that the addition of an aromatic ring into the adamantane
scaffold produced conformational rearrangements in the enzyme to stabilize
the aromatic ring of the benzohomoadamantane core. A screening cascade
permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis.
The administration of 22 improved the health status of
the animals and reduced pancreatic damage, demonstrating that the
benzohomoadamantane unit is a promising scaffold for the design of
novel sEHIs.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - Carla Calvó-Tusell
- CompBioLab Group, Departament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain
| | - Elena Valverde
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - Sílvia Osuna
- CompBioLab Group, Departament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis 95616, California, United States
| | - M Isabel Loza
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain
| | - José Brea
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain
| | - Concepción Pérez
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain
| | - María Isabel Rodríguez-Franco
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain
| | - Javier Pizarro-Delgado
- Pharmacology Section. Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Madrid 28029, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat 08950, Spain
| | - Rubén Corpas
- Institute of Biomedical Research of Barcelona (IIBB), CSIC and IDIBAPS, Barcelona 08036, Spain.,CIBER Epidemiology and Public Health (CIBERESP)-Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Christian Griñán-Ferré
- Pharmacology Section. Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - Mercè Pallàs
- Pharmacology Section. Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| | - Coral Sanfeliu
- Institute of Biomedical Research of Barcelona (IIBB), CSIC and IDIBAPS, Barcelona 08036, Spain.,CIBER Epidemiology and Public Health (CIBERESP)-Instituto de Salud Carlos III, Madrid 28029, Spain
| | - Manuel Vázquez-Carrera
- Pharmacology Section. Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, Madrid 28029, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, Esplugues de Llobregat 08950, Spain
| | - Bruce D Hammock
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis 95616, California, United States
| | - Ferran Feixas
- CompBioLab Group, Departament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, Girona 17003, Spain
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, Barcelona 08028, Spain
| |
Collapse
|
7
|
Griñán-Ferré C, Companys-Alemany J, Jarné-Ferrer J, Codony S, González-Castillo C, Ortuño-Sahagún D, Vilageliu L, Grinberg D, Vázquez S, Pallàs M. Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease. Int J Mol Sci 2021; 22:3409. [PMID: 33810307 PMCID: PMC8036710 DOI: 10.3390/ijms22073409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 03/22/2021] [Accepted: 03/22/2021] [Indexed: 11/17/2022] Open
Abstract
Niemann-Pick type C (NPC) disease is a rare autosomal recessive inherited childhood neurodegenerative disease characterized by the accumulation of cholesterol and glycosphingolipids, involving the autophagy-lysosome system. Inhibition of soluble epoxide hydrolase (sEH), an enzyme that metabolizes epoxy fatty acids (EpFAs) to 12-diols, exerts beneficial effects in modulating inflammation and autophagy, critical features of the NPC disease. This study aims to evaluate the effects of UB-EV-52, an sEH inhibitor (sEHi), in an NPC mouse model (Npc) by administering it for 4 weeks (5 mg/kg/day). Behavioral and cognitive tests (open-field test (OF)), elevated plus maze (EPM), novel object recognition test (NORT) and object location test (OLT) demonstrated that the treatment produced an improvement in short- and long-term memory as well as in spatial memory. Furthermore, UB-EV-52 treatment increased body weight and lifespan by 25% and reduced gene expression of the inflammatory markers (i.e., Il-1β and Mcp1) and enhanced oxidative stress (OS) markers (iNOS and Hmox1) in the treated Npc mice group. As for autophagic markers, surprisingly, we found significantly reduced levels of LC3B-II/LC3B-I ratio and significantly reduced brain protein levels of lysosomal-associated membrane protein-1 (LAMP-1) in treated Npc mice group compared to untreated ones in hippocampal tissue. Lipid profile analysis showed a significant reduction of lipid storage in the liver and some slight changes in homogenated brain tissue in the treated NPC mice compared to the untreated groups. Therefore, our results suggest that pharmacological inhibition of sEH ameliorates most of the characteristic features of NPC mice, demonstrating that sEH can be considered a potential therapeutic target for this disease.
Collapse
Affiliation(s)
- Christian Griñán-Ferré
- Pharmacology and Toxicology Section and Institute of Neuroscience, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (C.G.-F.); (J.C.-A.); (J.J.-F.)
| | - Júlia Companys-Alemany
- Pharmacology and Toxicology Section and Institute of Neuroscience, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (C.G.-F.); (J.C.-A.); (J.J.-F.)
| | - Júlia Jarné-Ferrer
- Pharmacology and Toxicology Section and Institute of Neuroscience, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (C.G.-F.); (J.C.-A.); (J.J.-F.)
| | - Sandra Codony
- Laboratory of Medicinal Chemistry (CSIC, Associated Unit), Faculty of Pharmacy and Food Sciences and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.C.); (S.V.)
| | - Celia González-Castillo
- Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Campus Guadalajara, Zapopan, 45201 Jalisco, Mexico;
| | - Daniel Ortuño-Sahagún
- Laboratorio de Neuroinmunobiología Molecular, Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Jalisco 44340, Mexico;
| | - Lluïsa Vilageliu
- Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain; (L.V.); (D.G.)
- Institut de Biomedicina de la UB (IBUB)-Institut de Recerca Sant Joan de Déu (IRSJD), 08028 Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBERER), 08028 Barcelona, Spain
| | - Daniel Grinberg
- Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain; (L.V.); (D.G.)
- Institut de Biomedicina de la UB (IBUB)-Institut de Recerca Sant Joan de Déu (IRSJD), 08028 Barcelona, Spain
- Centre for Biomedical Research on Rare Diseases (CIBERER), 08028 Barcelona, Spain
| | - Santiago Vázquez
- Laboratory of Medicinal Chemistry (CSIC, Associated Unit), Faculty of Pharmacy and Food Sciences and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (S.C.); (S.V.)
| | - Mercè Pallàs
- Pharmacology and Toxicology Section and Institute of Neuroscience, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; (C.G.-F.); (J.C.-A.); (J.J.-F.)
| |
Collapse
|
8
|
Griñán-Ferré C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol-Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, Pérez B, Loza MI, Brea J, Morisseau C, Hammock BD, Vázquez S, Pallàs M, Galdeano C. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease. Neurotherapeutics 2020; 17:1825-1835. [PMID: 32488482 PMCID: PMC7851240 DOI: 10.1007/s13311-020-00854-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with 3 compounds in clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's disease (AD). Evaluation of cognitive impairment and pathological hallmarks were used in 2 models of age-related cognitive decline and AD using 3 structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation pathology, and the number of amyloid plaques. This study suggests that inhibition of inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD.
Collapse
Affiliation(s)
- Christian Griñán-Ferré
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Jun Yang
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Carmen Escolano
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Dolors Puigoriol-Illamola
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Júlia Companys-Alemany
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain
| | - Rubén Corpas
- Institute of Biomedical Research of Barcelona, Consejo Superior de Investigaciones Científicas and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Rosselló, 149, E-08036, Barcelona, Spain
- Centros de Investigacion Biomedica en red Epidemiology and Public Health, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, E-28029, Madrid, Spain
| | - Coral Sanfeliu
- Institute of Biomedical Research of Barcelona, Consejo Superior de Investigaciones Científicas and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Rosselló, 149, E-08036, Barcelona, Spain
- Centros de Investigacion Biomedica en red Epidemiology and Public Health, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, E-28029, Madrid, Spain
| | - Belen Pérez
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona, E-08193, Barcelona, Spain
| | - M Isabel Loza
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, Universidad de Santiago de Compostela, Edificio CIMUS, Av. Barcelona, S/N, E-15706, Santiago de Compostela, Spain
| | - José Brea
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, Universidad de Santiago de Compostela, Edificio CIMUS, Av. Barcelona, S/N, E-15706, Santiago de Compostela, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Bruce D Hammock
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al Consejo Superior de Investigaciones Científicas), Department de Farmacologia, Toxicologia i Química Farmacèutica, Facultat de Farmàcia i Ciències de de l'Alimentació y Institut de Biomedicina, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Mercè Pallàs
- Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| | - Carles Galdeano
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine, University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain.
| |
Collapse
|
9
|
Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza MI, Brea JM, Saez E, Oyarzabal J, Pineda-Lucena A, Pérez B, Pérez C, Rodríguez-Franco MI, Leiva R, Osuna S, Morisseau C, Hammock BD, Vázquez-Carrera M, Vázquez S. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis. J Med Chem 2020; 63:9237-9257. [PMID: 32787085 DOI: 10.1021/acs.jmedchem.0c00310] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
In vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors, but the lipophilicity and metabolism of the adamantane group compromise their overall usefulness. Herein, we report that the replacement of a methylene unit of the adamantane group by an oxygen atom increases the solubility, permeability, and stability of three series of urea-based sEH inhibitors. Most of these oxa-analogues are nanomolar inhibitors of both the human and murine sEH. Molecular dynamics simulations rationalize the molecular basis for their activity and suggest that the presence of the oxygen atom on the adamantane scaffold results in active site rearrangements to establish a weak hydrogen bond. The 2-oxaadamantane 22, which has a good solubility, microsomal stability, and selectivity for sEH, was selected for further in vitro and in vivo studies in models of cerulein-induced AP. Both in prophylactic and treatment studies, 22 diminished the overexpression of inflammatory and endoplasmic reticulum stress markers induced by cerulein and reduced the pancreatic damage.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - Eugènia Pujol
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - Javier Pizarro
- Pharmacology, Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
| | - Ferran Feixas
- CompBioLab Group, Departament de Quı́mica and Institut de Quı́mica Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, 17003 Girona, Spain
| | - Elena Valverde
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - M Isabel Loza
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain
| | - José M Brea
- Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain
| | - Elena Saez
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Antonio Pineda-Lucena
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Belén Pérez
- Department of Pharmacology, Therapeutics and Toxicology, Institute of Neurosciences, Autonomous University of Barcelona, Bellaterra, 08193 Barcelona, Spain
| | - Concepción Pérez
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - María Isabel Rodríguez-Franco
- Institute of Medicinal Chemistry, Spanish National Research Council (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Rosana Leiva
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Universitat de Barcelona, 08028 Barcelona, Spain
| | - Sílvia Osuna
- CompBioLab Group, Departament de Quı́mica and Institut de Quı́mica Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany 69, 17003 Girona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, Davis, California 95616, United States
| | - Bruce D Hammock
- Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, Davis, California 95616, United States
| | - Manuel Vázquez-Carrera
- Pharmacology, Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.,Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain.,Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
| | - Santiago Vázquez
- Laboratori de Quı́mica Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Quı́mica Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| |
Collapse
|
10
|
Codony S, Valverde E, Leiva R, Brea J, Isabel Loza M, Morisseau C, Hammock BD, Vázquez S. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. Bioorg Med Chem 2019; 27:115078. [PMID: 31488357 DOI: 10.1016/j.bmc.2019.115078] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 07/31/2019] [Accepted: 08/25/2019] [Indexed: 01/18/2023]
Abstract
Soluble epoxide hydrolase (sEH) inhibitors are potential drugs for several diseases. Adamantyl ureas are excellent sEH inhibitors but have limited metabolic stability. Herein, we report the effect of replacing the adamantane group by alternative polycyclic hydrocarbons on sEH inhibition, solubility, permeability and metabolic stability. Compounds bearing smaller or larger polycyclic hydrocarbons than adamantane yielded all good inhibition potency of the human sEH (0.4 ≤ IC50 ≤ 21.7 nM), indicating that sEH is able to accommodate inhibitors of very different size. Human liver microsomal stability of diamantane containing inhibitors is lower than that of their corresponding adamantane counterparts.
Collapse
Affiliation(s)
- Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, Barcelona E-08028, Spain
| | - Elena Valverde
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, Barcelona E-08028, Spain
| | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, Barcelona E-08028, Spain
| | - José Brea
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, Spain
| | - M Isabel Loza
- Innopharma Screening Platform, Biofarma Research Group, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad de Santiago de Compostela, Spain
| | - Christophe Morisseau
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Bruce D Hammock
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, Barcelona E-08028, Spain.
| |
Collapse
|
11
|
Vázquez S, Codony S, Pizarro J, Loza MI, Brea JM, Morisseau C, Hammock BD, Vázquez‐Carrera M. Synthesis of a New Family of Soluble Epoxide Hydrolase Inhibitors,
in vitro
Profiling and
in vivo
Evaluation in a Murine Model of Acute Pancreatitis. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.508.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Javier Pizarro
- Department of Pharmacology, Toxicology and Therapeutic ChemistryUniversitat de Barcelona and IBUBBarcelonaSpain
| | - María Isabel Loza
- CIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - José M Brea
- CIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - Christophe Morisseau
- Department of Entomology and NematologyUC Davis Comprehensive Cancer Center, University of California, DavisDavisCA
| | - Bruce D Hammock
- Department of Entomology and NematologyUC Davis Comprehensive Cancer Center, University of California, DavisDavisCA
| | - Manuel Vázquez‐Carrera
- Department of Pharmacology, Toxicology and Therapeutic ChemistryUniversitat de Barcelona and IBUBBarcelonaSpain
| |
Collapse
|
12
|
Vázquez S, Codony S, Pizarro J, Pujol E, Valverde E, Loza I, Brea JM, Saez E, Oyarzabal J, Vázquez‐Carrera M, Leiva R. Novel Soluble Epoxide Hydrolase Inhibitors Featuring a 2‐Oxaadamantane Moiety: Synthesis,
in vitro
Profiling and
in vivo
Evaluation in Murine Models of Acute Pancreatitis. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.560.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Javier Pizarro
- PharmacologyUniversitat de Barcelona and IBUBBarcelonaSpain
| | - Eugènia Pujol
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Elena Valverde
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| | - Isabel Loza
- Drug Screening Platform/Biofarma Research GroupCIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - José M. Brea
- Drug Screening Platform/Biofarma Research GroupCIMUS Research Center. University of Santiago de Compostela (USC)Santiago de CompostelaSpain
| | - Elena Saez
- Small Molecule Discovery Platform, Molecular Therapeutics ProgramCenter for Applied Medical Research (CIMA)University of NavarraPamplonaSpain
| | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics ProgramCenter for Applied Medical Research (CIMA)University of NavarraPamplonaSpain
| | | | - Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)Universitat de Barcelona and IBUBBarcelonaSpain
| |
Collapse
|
13
|
Alonso JM, Quiroga S, Codony S, Turcu AL, Barniol-Xicota M, Pérez D, Guitián E, Vázquez S, Peña D. Palladium-catalyzed cocyclotrimerization of arynes with a pyramidalized alkene. Chem Commun (Camb) 2018; 54:5996-5999. [DOI: 10.1039/c8cc03188f] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A pyramidalized alkene and diverse arynes are generated in the presence of a Pd-catalyst to afford [2+2+2] cocycloaddition products.
Collapse
Affiliation(s)
- José M. Alonso
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
- Departamento de Química Orgánica
- Universidade de Santiago de Compostela
- 15782 Santiago de Compostela
- Spain
| | - Sabela Quiroga
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
- Departamento de Química Orgánica
- Universidade de Santiago de Compostela
- 15782 Santiago de Compostela
- Spain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)
- Facultat de Farmàcia i Ciències de l’Alimentació, and Institute of Biomedicine (IBUB)
- Universitat de Barcelona. Av. Joan XXIII, 27-31
- 08028 Barcelona
- Spain
| | - Andreea L. Turcu
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)
- Facultat de Farmàcia i Ciències de l’Alimentació, and Institute of Biomedicine (IBUB)
- Universitat de Barcelona. Av. Joan XXIII, 27-31
- 08028 Barcelona
- Spain
| | - Marta Barniol-Xicota
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)
- Facultat de Farmàcia i Ciències de l’Alimentació, and Institute of Biomedicine (IBUB)
- Universitat de Barcelona. Av. Joan XXIII, 27-31
- 08028 Barcelona
- Spain
| | - Dolores Pérez
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
- Departamento de Química Orgánica
- Universidade de Santiago de Compostela
- 15782 Santiago de Compostela
- Spain
| | - Enrique Guitián
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
- Departamento de Química Orgánica
- Universidade de Santiago de Compostela
- 15782 Santiago de Compostela
- Spain
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC)
- Facultat de Farmàcia i Ciències de l’Alimentació, and Institute of Biomedicine (IBUB)
- Universitat de Barcelona. Av. Joan XXIII, 27-31
- 08028 Barcelona
- Spain
| | - Diego Peña
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS)
- Departamento de Química Orgánica
- Universidade de Santiago de Compostela
- 15782 Santiago de Compostela
- Spain
| |
Collapse
|
14
|
Leiva R, Barniol-Xicota M, Codony S, Ginex T, Vanderlinden E, Montes M, Caffrey M, Luque FJ, Naesens L, Vázquez S. Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion. J Med Chem 2017; 61:98-118. [PMID: 29220568 DOI: 10.1021/acs.jmedchem.7b00908] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Two series of easily accessible anilines were identified as inhibitors of influenza A virus subtype H1N1, and extensive chemical synthesis and analysis of the structure-activity relationship were performed. The compounds were shown to interfere with low pH-induced membrane fusion mediated by the H1 and H5 (group 1) hemagglutinin (HA) subtypes. A combination of virus resistance, HA interaction, and molecular dynamics simulation studies elucidated the binding site of these aniline-based influenza fusion inhibitors, which significantly overlaps with the pocket occupied by some H3 HA-specific inhibitors, indicating the high relevance of this cavity for drug design.
Collapse
Affiliation(s)
- Rosana Leiva
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Joan XXIII, 27-31, Barcelona E-08028, Spain
| | - Marta Barniol-Xicota
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Joan XXIII, 27-31, Barcelona E-08028, Spain
| | - Sandra Codony
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Joan XXIII, 27-31, Barcelona E-08028, Spain
| | - Tiziana Ginex
- Department of Nutrition, Food Science and Gastronomy, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Prat de la Riba 171, Santa Coloma de Gramanet E-08921, Spain
| | | | - Marta Montes
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Joan XXIII, 27-31, Barcelona E-08028, Spain
| | - Michael Caffrey
- Department of Biochemistry & Molecular Genetics, University of Illinois at Chicago , 900 South Ashland Avenue, Chicago, Illinois 60607, United States
| | - F Javier Luque
- Department of Nutrition, Food Science and Gastronomy, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Prat de la Riba 171, Santa Coloma de Gramanet E-08921, Spain
| | - Lieve Naesens
- Rega Institute for Medical Research, KU Leuven , B-3000 Leuven, Belgium
| | - Santiago Vázquez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona , Av. Joan XXIII, 27-31, Barcelona E-08028, Spain
| |
Collapse
|